Rymti is not covered on the Reformulary. There are two etanercept biosimilars on the Reformulary that offer the same clinical value at a lower net cost to the plan. These biosimilars are Brenzys and Erelzi, and require Special Authorization.

Rymti is used to treat  
Ankylosing Spondylitis
Juvenile Idiopathic Arthritis
Psoriasis
Psoriatic Arthritis
Rheumatoid Arthritis